Akışa dön
67/100 Bullish 05.05.2026 · 04:35 Finrend AI ⏱ 1 dk 👁 10 TR

Johnson & Johnson Q1 Profit Exceeds Expectations

Johnson & Johnson (JNJ) reported first-quarter financial results that surpassed market expectations. The company's earnings per share (EPS) came in above analysts' forecasts, reflecting its strong operational structure and portfolio diversification. According to the released data, Johnson & Johnson's first-quarter net profit increased compared to the same period last year. The company stood out with growth in its pharmaceutical and medical device segments, where sales exceeded expectations due to sustained global demand. Revenue also beat analyst estimates. Johnson & Johnson contributed to total revenue with steady performance in its consumer health products segment. Management provided an optimistic outlook for the remainder of the year, stating that cost control and innovation-focused strategies would continue. Investors expect these strong quarterly results to positively impact the company's stock performance. Johnson & Johnson's key indicators confirm its maintained leadership position in the healthcare sector. This is not investment advice.

📊 JNJ — Piyasa Yorumu

▲ up · 60%

Johnson & Johnson (JNJ) reported better-than-expected first-quarter earnings, providing a positive catalyst. However, technical indicators paint a weak picture: the RSI at 36 is nearing oversold territory, the MACD is below its signal line, and the stock is trading below both its 20-day and 50-day moving averages. While a short-term recovery driven by the positive news is possible, upside is likely limited due to technical resistance and a prevailing downtrend. Therefore, although the directional bias is upward, conviction remains moderate.

RSI 14
36.3
MACD
-1.04
24h Δ
-1.51%

📊 ABBV — Piyasa Yorumu

■ neutral · 60%

Although ABBV stock has risen nearly 2% in the last 24 hours, its RSI of 57 indicates it is neither overbought nor oversold. The MACD remains below the signal line, suggesting weak short-term momentum. The price is trading just below the 20-day moving average, pointing to potential resistance. Since the news headline pertains to JNJ, no direct impact on ABBV is expected. Therefore, short-term direction remains uncertain.

RSI 14
57.3
MACD
0.77
24h Δ
1.97%

📊 BMY — Piyasa Yorumu

■ neutral · 60%

BMY stock could receive a sectoral tailwind from Johnson & Johnson's positive quarterly results, but the impact may remain limited. Technical indicators present a weak outlook: RSI at 39 is in the sell zone, MACD is below the signal line, and the price is below both the 20-day and 50-day moving averages. The 1% decline in the last close also confirms negative short-term momentum. Therefore, despite the positive news effect, the direction is assessed as neutral due to the weight of the technical picture.

RSI 14
39.3
MACD
-0.44
24h Δ
-1.04%

📊 PFE — Piyasa Yorumu

■ neutral · 30%

The news headline belongs to Johnson & Johnson and does not directly affect PFE, but the positive sentiment in the sector may have a limited short-term reflection. Technical indicators paint a weak picture: RSI at 42 is near the oversold zone, MACD is below the signal line, and the price is trading below SMA20 and SMA50. The last closing price was $26.32, slightly below the 20-day moving average ($26.48), indicating low short-term momentum. Despite a slight 0.2% rise in the last 24 hours, the overall technical structure does not signal a recovery. Therefore, the impact of the news remains limited, and the price is expected to trade sideways at current levels.

RSI 14
42.1
MACD
-0.08
24h Δ
0.21%
Canlı Grafikler

🔗 İlgili haberler

🧬 Buna benzer

AI tarafından yeniden derlenmiştir. Yatırım tavsiyesi değildir.